| Document |
Document Title |
|
WO/2024/091450A1 |
The present disclosure relates to compounds for treating cancer. The compounds may prevent conversion of non-stem cancer cells into cancer-initiating cells caused by radiation treatment.
|
|
WO/2024/091882A1 |
This patent document discloses novel compounds and methods of preventing or treating diseases or conditions related to Keapl-Nrf2interaction activity by use of the novel compounds. As direct inhibitors of Keapl-Nrf2 interaction, the comp...
|
|
WO/2024/092185A1 |
Provided herein are compounds useful for treating a viral infection caused by polyomavirus, e.g., by inhibiting polyomavirus replication. Also provided are compositions and methods including the provided compounds.
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/075825A1 |
The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity. The present invention pertains to a cyclopentane compound represented by formula (I) or a pharmacologically acceptable salt th...
|
|
WO/2024/074501A1 |
The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.
|
|
WO/2024/067560A1 |
Disclosed in the present invention are a sulfonamide compound and the medical use thereof as a STING inhibitor, specifically, a compound as represented by formula (I) or a pharmaceutically acceptable salt or ester or solvate thereof, whi...
|
|
WO/2024/034666A1 |
A ruthenium complex according to one aspect of the present disclosure is represented by general formula (1). In general formula (1), R1 represents a hydrogen atom, a phenyl group, or a monovalent substituent which is obtained by substitu...
|
|
WO/2024/026560A1 |
The present technology relates to multifunctionalized thiol conductor compounds which can be grafted onto polymers, and methods for making same. In certain embodiments, the compounds of the present technology can be grafted onto polymers...
|
|
WO/2024/029354A1 |
Provided is a novel compound that has photosensitivity such that said compound rapidly decomposes and generates an acid when irradiated with light rays having a wavelength of 20 nm or lower. A sulfonium salt according to the present in...
|
|
WO/2024/031002A1 |
This disclosure includes pesticidal compounds, compositions, and related agricultural methods.
|
|
WO/2024/028999A1 |
The present invention addresses the problem of providing a method for efficiently producing an N-[4-methylaminobenzoyl]-L-glutamic acid diethyl ester, which is a pharmaceutical intermediate. In this method for producing an N-[4-methylami...
|
|
WO/2024/025970A1 |
A membrane electrode assembly includes an anion conducting membrane and electrodes. The membrane electrode assembly is made from two different polymers in one system. The membrane electrode assembly of this invention is suitable for use ...
|
|
WO/2024/024844A1 |
The present invention provides: a method for producing an active ray-sensitive or radiation-sensitive resin composition, the method comprising a step (X) for mixing a specified onium salt compound (1) with a specified salt compound (2) i...
|
|
WO/2024/020409A1 |
The present disclosure, in part, is directed to compositions comprising a compound of formula (I): wherein the compositions are substantially free of an impurity, processes of producing thereof, and uses thereof.
|
|
WO/2024/017858A1 |
The invention relates to novel compounds having the general formula (I) wherein R1, R2, X1, X2, X3 and W are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2024/011093A1 |
The present invention relates to the treatment of a ALS patient with oral fausdil at a dose of 180-240 mg/day, wherein the patient is treated beginning at least 24 months following disease onset. This results in an anticipated 25-50% red...
|
|
WO/2024/011094A1 |
The present invention relates to the treatment of an ALS patient having disease onset of at least 24 months prior to initiation of treatment with fausdil. Fasudil is administered at a dose of 60-240 mg/day according to specific treatment...
|
|
WO/2024/002897A1 |
The present invention relates to a method for producing bis(fluorosulfonyl)imide acid, which is economically feasible at industrial scale and which provides a high-purity product.
|
|
WO/2024/000062A1 |
The present technology relates to thiol functionalized conductors which can be grafted onto polymers and methods for making same. In certain embodiments, the thiol functionalized conductors can be grafted onto polymers with low Tg to syn...
|
|
WO/2023/250318A1 |
Anthraquinone analogs that have anticancer properties are disclosed. Pharmaceutical formulations in forms suitable for the delivery of the compounds to a subject in need thereof are disclosed. Methods of using the compounds for treating ...
|
|
WO/2023/250140A1 |
Disclosed is a method for treating subarachnoid hemorrhage (SAH) and/or reducing the incidence of subsequent cerebral vasospasm in a patient. The method involves administering a therapeutically effective amount of a first compound or a p...
|
|
WO/2023/236920A1 |
This disclosure provides compounds of Formula (1), compositions comprising the same, and methods of using the same, including uses in modulating SARM1 and treating various diseases and conditions, e.g., those caused by axonal degeneration.
|
|
WO/2023/235975A1 |
The present technology relates to methods for the synthesis of a lithium single-ion monomer which comprises simultaneously reacting a sulfonyl chloride compound with i) a fluorinated sulfonamide compound and ii) a compound that is suitab...
|
|
WO/2023/229295A1 |
The present invention relates to a phenylpropene derivative, and a pharmaceutical composition for the prevention or treatment of cancer, comprising the phenylpropene derivative as an active ingredient. The phenylpropene derivative disclo...
|
|
WO/2023/219010A1 |
This resin composition contains a resin and at least one infrared-absorbing dye A selected from a dye A1 represented by formula (1) and die multimers A2 including two or more dye structures derived from the dye A1 per molecule. The prese...
|
|
WO/2023/214552A1 |
The present disclosure provides: a trifluoromethane sulfonylation agent composition containing a compound represented by general formula (1) or (11) disclosed in the description; and a method for producing a trifluoromethanesulfonyloxy c...
|
|
WO/2023/207949A1 |
The present invention provides a fused ring compound represented by formula I and use thereof. The fused ring compound of the present invention has a selective inhibitory activity against Nav1.8, and can be used as a Nav inhibitor and us...
|
|
WO/2023/209109A1 |
The present invention relates to an hexahydro-s-indacene compound of Formula (I) or its pharmaceutically acceptable salt wherein A is selected from the group consisting of (A1), (A2) and (A3) as defined in the claims. The compounds of th...
|
|
WO/2023/205237A1 |
Disclosed are one or more compounds comprising chemically modified gamma-hydroxybutyrate (GHB), 2-hydroxytetrahydrofuran, and/or 1,4-butanediol, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are...
|
|
WO/2023/196581A1 |
Compatibilizing agents for use in a wide variety of filled and unfilled liquid matrices and compositions comprising the agents are described. The compatibilizing agents can reduce the viscosity of the matrices and/or improve the stabilit...
|
|
WO/2023/181030A1 |
The present invention relates to novel a pesticidally and/or herbicidally active compounds, agrochemical composition thereof, methods of preparation thereof, and uses thereof for controlling the growth of undesirable plants (e.g., weeds)...
|
|
WO/2023/177877A1 |
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist co...
|
|
WO/2023/171597A1 |
Provided are high-purity styrenesulfonic acids having markedly decreased bound bromine and polymers thereof that are useful as modifiers for secondary batteries, dopants for conductive polymers, additives for semiconductor abrasives and ...
|
|
WO/2023/168108A2 |
This disclosure provides reagents and processes for the synthesis of organic compounds, more particularly reagents and processes for the asymmetric synthesis of sulfur(VI) containing organic compounds.
|
|
WO/2023/165217A1 |
Disclosed in the present application are a 1,6-diyne compound and a preparation method therefor, a product obtained using the 1,6-diyne compound as a raw material and the use thereof, which belong to the field of organic synthesis. A com...
|
|
WO/2023/159303A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula I or Formula II and compositions thereof for use in the treatment of cancer. In particular, the Myc- Max inhibitory compounds may be useful for the treatmen...
|
|
WO/2023/157635A1 |
The present invention provides an actinic-ray-sensitive or a radiation-sensitive resin composition having excellent roughness performance and roughness performance after the passage of time. This actinic-ray-sensitive or radiation-sensit...
|
|
WO/2023/158795A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2023/152754A1 |
The present invention relates to a crystalline rosuvastatin allyl ester (1 ), and its use in medicine, in particular as a prodrug of rosuvastatin,, a pharmaceutical' agent useful, for example, in the treatment of hyperlipidemia, hypercho...
|
|
WO/2023/144798A1 |
Certain embodiments of the invention provide ionizable lipids having optimized clearance properties. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising ionizable lipids, methods of making the lipid ...
|
|
WO/2023/146513A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction be...
|
|
WO/2023/137309A2 |
The present invention relates to protoporphyrinogen IX oxidase (PPO) inhibitors of the general formula (I) where the variables are defined herein. The invention features processes and intermediates for preparing the compounds of formula ...
|
|
WO/2023/132352A1 |
The present invention provides a method that is for producing an amide compound, that comprises obtaining an amide compound by causing a reaction between a carboxylic acid compound and an amine compound in the presence of a condensing ag...
|
|
WO/2023/120292A1 |
Provided is a method for producing a sulfonamide derivative, the method being characterized by including a step of causing a compound having a nitro group to react with a compound having a thiol group under light irradiation, and forming...
|
|
WO/2023/120250A1 |
Provided is an actinic-ray-sensitive or radiation-sensitive resin composition, etc. that, when forming an ultra-fine pattern (for example, a line and space pattern of 25 nm or less, or a hole pattern with a hole diameter of 25 nm or less...
|
|
WO/2023/119910A1 |
Provided is a radiation-sensitive composition containing: a polymer having an acid dissociable group; and at least one compound (b) selected from the group consisting of a compound represented by formula (1) and a compound represented by...
|
|
WO/2023/122276A1 |
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the c...
|
|
WO/2023/113086A1 |
The present invention relates to: a salt compound comprising a negative ion having a specific structure represented by chemical formula 1, and a positive ion represented by chemical formula 2; a quencher including the salt compound; and ...
|
|
WO/2023/114615A1 |
A redox-based strategy for bioconjugation of tryptophan uses oxaziridine reagents that mimic oxidative cyclization reactions in indole-based alkaloid biosynthetic pathways to achieve highly selective and rapid tryptophan labeling.
|
